Effects of Silica and Asbestos Fibres on the Efferocytosis Capacities of Macrophages
NCT ID: NCT04473742
Last Updated: 2022-01-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
23 participants
INTERVENTIONAL
2021-03-31
2021-12-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biological Evaluation of a Novel Anti-inflammatory Treatment in Immune-mediated Inflammatory Diseases
NCT02839278
Impact of Aging on Cytokine Production by Innate Immune Cells
NCT02660723
Characterization of a Functional Test for Mediterranean Family Fever Screening - 2
NCT04478409
Vasculopathy, Inflammation and Systemic Sclerosis
NCT02562079
Novel PET Radioligand as an Inflammatory Biomarker in Musculoskeletal Conditions
NCT03912428
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* 2 x 6mL serum tubes for the assessment of Antinuclear Antibody (ANA) positivity, serum high-mobility group box 1 (HMGB1) and osteopontin for patients exposed to asbestos
* 1 x 6mL serum tube for serum HMGB1 and osteopontin for patients exposed to silica
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients exposed to silica
Blood collection
4 EDTA tubes for 24 mL blood collection
Blood sample
1 drying tube for 6 mL blood collection
Patients exposed to asbestos fibres
Blood collection
4 EDTA tubes for 24 mL blood collection
Blood sample
2 drying tubes for 12 mL blood collection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood collection
4 EDTA tubes for 24 mL blood collection
Blood sample
2 drying tubes for 12 mL blood collection
Blood sample
1 drying tube for 6 mL blood collection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Addressed to the department of occupational disease
* With a history of asbestosis or silica exposure evaluated by a dedicated questionnaire and a throughout examination of the history of occupations, according to standard procedures for the follow-up of at risk workers.
* Persons who received an oral and written information on the protocol and signed the informed consent form
Exclusion Criteria
* Subject legally protected (under judicial protection, guardianship), persons deprived of liberty
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rennes University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de Rennes
Rennes, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
35RC20_8878_MacFibOsis
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.